

Real-Time PCR Technology for Cancer Diagnostics

PHILIP S. BERNARD* and CARL T. WITTEW

Background: Advances in the biological sciences and technology are providing molecular targets for diagnosing and treating cancer. Current classifications in surgical pathology for staging malignancies are based primarily on anatomic features (e.g., tumor-node-metastasis) and histopathology (e.g., grade). Microarrays together with clustering algorithms are revealing a molecular diversity among cancers that promises to form a new taxonomy with prognostic and, more importantly, therapeutic significance. The challenge for pathology will be the development and implementation of these molecular classifications for routine clinical practice.

Approach: This article discusses the benefits, challenges, and possibilities for solid-tumor profiling in the clinical laboratory with an emphasis on DNA-based PCR techniques.

Content: Molecular markers can be used to provide accurate prognosis and to predict response, resistance, or toxicity to therapy. The diversity of genomic alterations involved in malignancy necessitates a variety of assays for complete tumor profiling. Some new molecular classifications of tumors are based on gene expression, requiring a paradigm shift in specimen processing to preserve the integrity of RNA for analysis. More stable markers (i.e., DNA and protein) are readily handled in the clinical laboratory. Quantitative real-time PCR can determine gene duplications or deletions. Furthermore, melting curve analysis immediately after PCR can identify small mutations, down to single base changes. These techniques are becoming easier and faster and can be multiplexed. Real-time PCR methods are a favorable option for the analysis of cancer markers.

Summary: There is a need to translate recent discoveries in oncology research into clinical practice. This requires

objective, robust, and cost-effective molecular techniques for clinical trials and, eventually, routine use. Real-time PCR has attractive features for tumor profiling in the clinical laboratory.

© 2002 American Association for Clinical Chemistry

The sequence for most of the human genome is now publicly available and can be applied to understand, characterize, and treat complex diseases such as cancer. The biological differences between tumors that account for variations in morphology and clinical behavior can be analyzed using gene expression microarrays (1–5), comparative genomic hybridization (CGH)¹ (6–9), fluorescence in situ hybridization (10, 11), quantitative PCR (12), and mutation analysis (13, 14). Normal cell regulation can be disrupted by many factors, including viral infections (15, 16), DNA methylation (17), and sequence alterations (18, 19). Cancer develops when these insults affect the function of genes controlling cell division, cell repair, apoptosis, and angiogenesis. Current molecular techniques are providing the tools needed to investigate tumor biology and to discover the genetic and epigenetic causes of cancer.

Microarrays together with clustering analysis have allowed genome-wide expression patterns in biological systems to be deciphered and compared. Hierarchical clustering of microarray data groups together genes that are coordinately expressed under different conditions (20–22). Using microarrays, investigators have developed gene expression-based classifications for many malignancies, including lymphoma (4), leukemia (3), lung carcinoma (5), and both hereditary (23) and sporadic (1, 2) breast tumors. A unique signature can be found within the genetic programming of each tumor, revealing its molecular history. This allows tumor histology to be molecularly dissected based on the unique expression

Department of Pathology, University of Utah School of Medicine, 30 North 1900 East, Salt Lake City, UT 84132.

*Author for correspondence. Fax 801-581-4517; e-mail phil.bernard@path.utah.edu.

Received April 4, 2002; accepted May 9, 2002.

¹ Nonstandard abbreviations: CGH, comparative genome hybridization; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; Cp, crossing point; and topo, topoisomerase.

profile of each cell type in the sample. For example, in breast tumors, the unique gene expression of mammary tumor cells can be distinguished from other cell types within the sample, such as lymphocytes and stromal cells (1, 24). In addition, molecular subtypes within a given histologic classification can often be identified. For example, there are two classes of B-cell chronic lymphocytic leukemia (3), two classes of diffuse large B-cell lymphoma (4), five classes of non-small cell lung tumors (including three types of adenocarcinoma) (5), and at least four molecular classes of invasive ductal cell breast carcinoma (1, 25). Finally, these molecular subtypes are clinically significant because they predict patient outcome and explain variability seen in the natural course of certain tumors with the same anatomic diagnosis (2–4, 25).

Additional information about the nature of a tumor can be gleaned from its associated mutations. A mutation within a particular gene is sometimes reflected by the gene expression profile (3, 23). By far the most common mutations in human malignancy are sporadic mutations in tumor suppressor genes such as *p53*. A *p53* gene mutation is found in >50% of all malignancies and is particularly common in carcinomas of the head and neck, lung, skin, bladder, and colon (19). Mutations in *p53* correlate with aggressive histologic features (26), early invasive potential, and resistance to therapy (13, 27–29). In breast cancer, where the frequency of a *p53* mutation is estimated at 20–30% (13, 27), the detection of a *p53* mutation by nucleic acid analysis is an independent predictor of poor response to tamoxifen, based on multivariate analysis (13). Nucleic acid methods of mutation detection are preferred over immunohistochemistry (IHC) for determining *p53* status. Although *p53* IHC is associated with mutation status in some tumors (e.g., colorectal), the concordance is generally poor (30, 31). IHC is a convenient method to score for molecular markers in surgical pathology, but it is subject to variability from differences in antibody specificity, scoring criteria, and storage (32, 33). Additional advantages of nucleic acid analysis include correlating specific mutations to treatment response and providing a marker for monitoring residual disease (34, 35).

The need for solid-tumor molecular markers in pathology is clear. However, how these new tests will be best implemented is less certain. For example, specimens received in surgical pathology are routinely formalin fixed and paraffin embedded to preserve the architecture of the tissue. This processing makes recovery of mRNA unreliable; thus, expression analysis by microarray or reverse transcription-PCR is not feasible unless there is a paradigm shift in sample procurement for solid tumors. Markers in the form of DNA and protein are typically more stable than RNA, allowing them to be used within the current framework of surgical pathology for determining mutation status and gene expression.

Quantitative Analysis

LESSONS LEARNED FROM HER-2/neu TESTING


IHC is a semiquantitative technique for protein expression that allows convenient interpretation by an anatomic pathologist using light microscopy. Although IHC is cost-effective and allows histology to be simultaneously evaluated with the marker of interest, it is subjective and prone to error. This has been particularly apparent in the evaluation of breast cancer for HER-2 protein overexpression (36, 37). A positive HER-2 status indicates aggressive tumor transformation and a poor prognosis (38–40). The IHC-based “HercepTest” for HER-2 was approved to predict response to trastuzumab (Herceptin). However, it is difficult to differentiate between weak positive and background staining. In addition, different commercially available antibodies can give different results (41). The difficulties with HER-2 IHC has led many laboratories to offer fluorescence in situ hybridization (FISH) as a method to determine *HER-2* gene amplification. There are now two Food and Drug Administration-approved FISH-based tests for *HER-2* status (42). Although there is good concordance between the FISH methods (98%), there is generally poor agreement between FISH and IHC (43, 44). Experience with HER-2 clinical testing underscores the need for consistency and reliability in solid-tumor molecular assays, a need that will become even more acute as more targets are discovered and used.

REAL-TIME QUANTITATIVE PCR

In pace with the development of microarray technologies have been advances in real-time quantitative PCR. Real-time quantitative PCR is a homogeneous method that includes both amplification and analysis with no need for slab gels, radioactivity, or sample manipulation. There are now several platforms commercially available for combining thermal cycling with fluorescence acquisition (45). The fluorescence of DNA dyes or probes is monitored each cycle during PCR. At a certain point during cycling, the product accumulates enough to increase fluorescence above background. The point where fluorescence rises above background noise is best quantified as the second derivative maximum [crossing point (Cp)] of the curve and correlates to the amount of starting copies within a PCR reaction (46).

As the number of initial template copies increases, fluorescence appears sooner and the Cp is lower. The relative copy number between two samples (experimental and control) can be determined by the difference in their Cp values (Fig. 1A). Because PCR is an exponential process, the relative copy number is equal to the PCR efficiency raised to the power, ΔC_p . Because it may be difficult to know the total amount of DNA present in different samples, results of the test gene are often normalized to a reference gene presumed to be invariant (Fig. 1B). Regions of genomic stability (i.e., not altered) for a given tumor type can be identified by CGH studies and can be used for DNA controls. An inexpensive and

A. Calculating Relative Copy Numbers



B. Changes in Copy Number Compared to Reference




Fig. 1. Relative quantification by real-time PCR.

(A), the amounts of target in an experimental sample and a control sample are compared after PCR amplification and fluorescence monitoring each cycle. For example, genomic DNA may be analyzed to assess gene amplification or deletion. Expression of mRNA may also be studied after reverse transcription. The sample with the greater amount of DNA (or cDNA) will show an earlier increase in fluorescence. The second derivative maxima of the curves (vertical dotted lines) are determined as fractional cycle numbers. The relative copy number between samples is the PCR efficiency (eff) raised to the difference between fractional cycle numbers (ΔC). The calculation assumes that the PCR efficiency is the same between samples. The PCR efficiency is usually between 1.7 and 2.0. As a first approximation, an efficiency of 2 is often assumed. This analysis assumes that the starting amount of material (DNA or cDNA) in each sample is the same. (B), another option is to use a test target normalized to a reference target. The amount of starting material in each sample is normalized to a reference (Ref) or housekeeping gene. Both experimental and control samples are amplified for both the test and reference targets. Any difference in the amount of starting material is normalized by the results of the reference target amplification. This method assumes that the reference target is invariant between samples and that the PCR efficiency for each target does not vary between samples. As a first approximation, an efficiency of 2 is often assumed for both targets and has become known as the $\Delta\Delta C$ method.

common method to validate microarray experiments is relative quantification by real-time PCR using SYBR Green I as a fluorescent indicator of double stranded DNA production (47).

The correlation between C_p and starting copy and the use of these values to calculate PCR amplification efficiency are shown in panels A and B, respectively, of Fig. 2. The PCR amplification curves were generated with hybridization probes specific for the serum *albumin* gene [primer/probe sequences and amplification conditions can be found as an online supplement at LightCycler University (http://www.idahotech.com/lightcyler_u/index.html)]. Genomic leukocyte DNA was used at decreasing concentrations in a series of 10-fold dilutions. The fluorescence was acquired every cycle and then plotted against cycle number to construct an amplification curve at each dilution (Fig. 2A). Linear regression through a plot of the C_p s at each dilution against the log of genomic DNA gives the average efficiency of the PCR reaction (Fig. 2B). This is calculated using the formula:

$$\text{Efficiency} = 10^{\frac{-1}{\text{slope}}}$$

The y -intercept of the calibration curve is a function of the minimum detectable amplicon (48).

REAL-TIME MULTIPLEX PCR FOR DIAGNOSTICS

Real-time quantitative PCR can analyze multiple genes simultaneously within a single reaction. The main advantages of multiplexing over single-target analysis are the ability to provide internal controls, lower reagent costs, and preservation of precious samples. Multiplexing can be particularly important when there is a need to analyze several targets from microdissected tissue. Microdissection of solid tumor samples is usually necessary when determining gene copy numbers because the presence of DNA from normal diploid cells will interfere. Protocols for obtaining nucleic acids from microdissected tissue are well established (49). Two genes in which quantitative DNA analysis may be important for prognosis and treatment of breast cancer are *HER-2* and *topoisomerase II α* (*topo II α*). In ~20% of breast cancers, the *HER-2* gene becomes amplified at the DNA level, leading to an increase in message and overexpression of the protein (37, 44). The *topo II α* gene is physically located near *HER-2* within the chromosome band region 17q12-q21, an area that is frequently mutated in breast tumors (6, 50, 51). DNA amplification of *HER-2* can occur concomitantly with *topo II α* alterations (amplification or deletion), and changes in *topo II α* copy number may dictate response to chemotherapy with topo II inhibitor drugs (52, 53).




Fig. 2. Establishing PCR efficiency.

(A), the overall efficiency of PCR within a run can be found by use of a dilution series of DNA (e.g., leukocyte) to generate amplification curves at different concentrations of template. (B), the overall efficiency of PCR for a given primer and probe set can be calculated from the linear regression through a plot of Cp vs log ng DNA. For *albumin*, the slope of the trend line was -3.52 , yielding an efficiency of 1.92.

We used a three-color multiplex PCR reaction to simultaneously determine starting copy numbers of *HER-2* and *topo II α* relative to the control gene *albumin*. Acceptor dyes LCR640 (*HER-2*), Cy5 (*albumin*), and LCR705 (*topo II α*) were paired with fluorescein in three sets of adjacent hybridization probes. Each target was identified by the different emissions of the acceptor-labeled hybridization probes. Overlap between the emission spectra of these dyes was compensated in software to isolate the unique signal from each probe (54). Multiplexed reactions within the run were used to establish the amplification efficiency of each gene. If all three targets are present in same number of copies and each target amplifies with the same efficiency, then all three targets should have the same Cp. Fig. 3 compares the amplification of wild-type genomic leukocyte DNA (Fig. 3A) and DNA isolated from a breast tumor (Fig. 3B). As expected, the Cps for all three targets in the wild-type genomic DNA are the same, but in the tumor sample, both *HER-2* and *topo II α* have Cps shifted three cycles earlier than *albumin*. This corresponds to an eightfold amplification of these genes. This tumor sample was independently determined to have DNA amplification with mRNA overexpression for both genes by CGH and cDNA microarray analysis (1, 50).




Fig. 3. Determining efficiency and gene copy numbers using three-color multiplexing.

There is greater variation in PCR efficiency between runs than within a run. We established the efficiency of amplification for three targets within a run using color multiplexing and used the calculated efficiencies to determine gene amplification in breast tumors. After color compensation and correction for differences in PCR efficiency, Cps of *HER-2*, *topo II α* , and *albumin* were compared in healthy leukocytes and breast tumor cells. All three genes had nearly the same Cp for wild-type leukocyte DNA (A). However, the DNA from the breast tumor cells showed an early three-cycle shift for both *HER-2* and *topo II α* , corresponding to an eightfold (2^3) amplification over *albumin* (B).

Mutation Analysis

REAL-TIME PCR FOR MUTATION DETECTION IN SOLID TUMORS

Mutations in DNA can include large rearrangements, such as translocations, inversions, and gene amplifications/deletions, as well as small alterations, such as point mutations and base insertions/deletions. Large alterations frequently occur in hematologic malignancies and are routinely analyzed by DNA techniques in cytogenetics (e.g., chromosomal spread and FISH) (10, 11). In contrast, small alterations frequently occur in carcinomas, and there are few, if any, routine clinical assays for identifying small somatic alterations in solid tumors.

Somatic mutations are acquired during the evolution of many tumors and may significantly impact the course of malignancy. The *p53* tumor suppressor gene is the most frequently mutated gene in human cancers. Approximately 90% of all mutations in *p53* occur within the


DNA-binding domain (exons 5–8), and most (87%) are single-base changes (19). Mutations in exons 5–8 are the best indicators of outcome (13, 27, 29, 55). Studies suggest that particular hotspot mutations in *p53* (e.g., codon 273) may confer resistance to the anthracyclines (55, 56), which are the first-line therapy in metastatic breast cancer. The presence of a *p53* mutation may be further exploited for monitoring recurrence or therapy response. For example, tumor cell death releases mutated *p53* nucleic acids into the bloodstream that can be detected in the serum of patients (34, 35). The detection (and even quantification) of this mutated DNA can be used for periodic monitoring. Despite the demonstrated value of *p53*, routine clinical testing of *p53* continues to be debated. The reasons for this include conflicting results between testing methodologies and finding a technique that is amenable to use in the clinical laboratory.

A variety of scanning methods and direct sequencing are used to establish associations between genotype and disease (57). Conventional scanning methodologies use slab gels to resolve mobility shifts attributable to mutations that cause single-stranded conformational changes or changes in heteroduplex melting. Gel techniques that differentiate homo- and heteroduplexes by exploiting differences in duplex stability include denaturant gradient gel electrophoresis (58), constant denaturant gel electrophoresis (59), and temporal temperature gradient gel electrophoresis (60). Alternatively, heteroduplexes may be detected by chemical or enzymatic cleavage followed by gel fragment sizing (61). Advances in scanning methodologies include the incorporation of fluorescence with single-strand conformational polymorphism analysis and the use of denaturing HPLC (62, 63). Methods capable of scanning for somatic mutations in a rapid, sensitive, and

cost-effective manner will have the greatest utility in the clinical laboratory.

Fluorescent hybridization probes are often used in the clinical laboratory for homogeneous genotyping. For example, melting curve analysis with hybridization probes detects small germline mutations/polymorphisms in the genes that cause common inherited diseases, such as cystic fibrosis (64), venous thrombosis (65, 66), emphysema (67), hemochromatosis (68), and hypercholesterolemia (54, 69). Melting curve analysis with the double-stranded DNA-binding dye SYBR Green I has been used to detect DNA methylation (70), which can produce transcriptional silencing. In addition, melting curve analysis of single-labeled probes can be used to scan for somatic mutations. Fig. 4 shows the detection of *p53* mutations in exons 6 (Fig. 4A) and exon 8 (Fig. 4B) from two different colon cancers by use of a series of overlapping fluorescein-labeled oligonucleotides complementary to a wild-type *p53* sequence. The probes are designed so that fluorescence decreases on target annealing because of deoxyguanosine quenching (71). After amplification in a LightCycler, the instrument begins a melting program where the reactions are cooled to anneal the probes and then slowly heated (0.1 °C/s) while fluorescence is continuously monitored. Somatic mutations are identified by changes from a characteristic wild-type melting curve profile. When melting curves from nonmutated and mutated colon cancer samples are compared, additional melting peaks (Fig. 4A) or changes in peak-area ratios (Fig. 4B) indicate a sequence alteration under the probe. As many as three probes have been placed in one tube for melting temperature multiplexing, scanning a region of ~100 bp.

A. Mutation Creating Additional Peak



B. Mutation Creating Change in Peak Areas




Fig. 4. Homogeneous scanning of *p53* in colorectal tumors.

Overlapping fluorescein-labeled probes were used to scan colon cancers for mutations in exons encoding the DNA-binding domain of *p53*. Multiple probes complementary to the wild-type sequences were placed within the same reaction, and the different sites were identified by their specific probe/target duplex melting temperatures. The position of each probe/target melting temperature and the relative ratio of the melting peak areas determined wild-type profiles. For example, an aberrant profile in exon 6 (A) was detected from an additional melting peak, and a mutation in exon 8 (B) was detected from a change in peak areas. Both mutations were confirmed by sequencing, which showed a G-to-T base change (C:T mismatch) under the lower melting probe/target duplex in exon 6 and a G-to-A base change (C:A mismatch) under the higher melting probe site in exon 8.

Summary

Cancer research is focusing on the importance of new molecular markers (72). The integration of molecular markers into existing histomorphologic classifications in surgical pathology will provide additional stratification for a more accurate prognosis. Furthermore, a molecular definition of cancer may often allow the guidance of therapy and the ability to monitor residual disease.

The technology used today in cancer research, such as expression microarrays and CGH, allow genome-wide scanning and the discovery of altered genes involved in cancer. Expression microarrays can identify coordinately regulated genes, defining pathways that explain the different clinical behaviors observed between tumors. CGH can provide genome-wide coverage for the identification of regions that are DNA amplified or deleted during tumor evolution. By combining these technologies, important biological pathways can be identified on multiple molecular levels. For example, CGH has identified a region of DNA amplification on chromosome 17q that is has been shown by expression microarray to involve an amplicon containing *HER-2*, *Grb-7*, and *topo II α* (1,50). Identification of targets at the DNA level allows the option of target validation retrospectively on formalin-fixed, paraffin-embedded tissue blocks. It also allows these targets to be easily integrated into the current flow of sample processing in pathology. Microarrays and CGH are powerful tools that can be used to find differences between tumors and to find common mechanisms leading to malignancy. In the near future, tumors will be defined and treated based on biological pathways that drive malignant cell proliferation and metastasis (73–76), rather than solely on histologic appearance.

The platforms for providing clinical molecular assays are still developing. Expression microarrays and CGH are invaluable to understanding the biology of cancer. However, once cancer genes and control genes have been identified, these methods may be superfluous for clinical diagnostics. Real-time PCR will play an increasingly important role in clinical testing because it can provide information about gene expression, gene amplification or loss, and small alterations (e.g., point mutations). In addition, it can be applied to detect and quantify viral causes of cancer, such as Epstein–Barr virus (16) and human papillomavirus (77). The use of real-time PCR for molecular diagnostics is attractive because it is objective, rapid, versatile, and cost-effective and can be performed on small tissue samples.

We thank Haleigh Millward for technical assistance, Dr. Wade Samowitz (University of Utah, Department of Pathology, Salt Lake City, UT) for the gift of colon cancer DNA, and Dr. Charles Perou (University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC) for the gift of the BC-2 breast tumor DNA. This work was in part supported by NIH

Grant GM60063-03. The LightCycler and related technologies are licensed from The University of Utah to Idaho Technology and Roche Applied Systems. C.T.W. holds equity interest in Idaho Technology. P.S.B. is a consultant for Idaho Technology.

References

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature* 2000;406:747–52.
2. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 2002;415:530–6.
3. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. *J Exp Med* 2001;194:1639–47.
4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 2000;403:503–11.
5. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, et al. Diversity of gene expression in adenocarcinoma of the lung. *Proc Natl Acad Sci U S A* 2001;98:13784–9.
6. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. *Genes Chromosomes Cancer* 1998;21:177–84.
7. Watanabe T, Imoto I, Kosugi Y, Ishiwata I, Inoue S, Takayama M, et al. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. *Gynecol Oncol* 2001;81:172–7.
8. De Angelis PM, Stokke T, Beigi M, Mjaland O, Clausen OP. Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer. *Int J Colorectal Dis* 2001;16:38–45.
9. Wiltshire RN, Rasheed BK, Friedman HS, Friedman AH, Bigner SH. Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification. *Neuro-oncol* 2000;2:164–73.
10. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 2000;343:1910–6.
11. Gebhart E, Rosler W, Gramatzki M, Trautmann U. FISH monitoring of 100 courses of human leukemias: the cytogenetic viewpoint. *Int J Oncol* 2001;19:617–23.
12. Lehmann U, Glockner S, Kleeberger W, von Wasielewski HF, Kreipe H. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. *Am J Pathol* 2000;156:1855–64.
13. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. *Cancer Res* 2000;60:2155–62.
14. Iacopetta B, Griou F, Powell B, Soong R, McCaul K, Seshadri R. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. *Clin Cancer Res* 1998;4:1597–602.
15. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. *JAMA* 2001;286:3106–14.

16. Fan H, Gulley ML. Epstein-Barr viral load measurement as a marker of EBV-related disease. *Mol Diagn* 2001;6:279–89.
17. Rountree MR, Bachman KE, Herman JG, Baylin SB. DNA methylation, chromatin inheritance, and cancer. *Oncogene* 2001;20:3156–65.
18. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. *Cell* 2002;108:171–82.
19. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. *Adv Cancer Res* 2000;77:81–137.
20. Spellman PT, Sherlock G, Zhang MQ, Iyer VR, Anders K, Eisen MB, et al. Comprehensive identification of cell cycle-regulated genes of the yeast *Saccharomyces cerevisiae* by microarray hybridization. *Mol Biol Cell* 1998;9:3273–97.
21. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, et al. Functional discovery via a compendium of expression profiles. *Cell* 2000;102:109–26.
22. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A* 1998;95:14863–8.
23. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene-expression profiles in hereditary breast cancer. *N Engl J Med* 2001;344:539–48.
24. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. *Proc Natl Acad Sci U S A* 1999;96:9212–7.
25. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 2001;98:10869–74.
26. Soong R, Iacopetta BJ, Harvey JM, Sterrett GF, Dawkins HJ, Hahnel R, et al. Detection of p53 by rapid PCR-SSCP and its association with poor survival in breast cancer. *Int J Cancer* 1997;74:642–7.
27. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. *Cancer Res* 2001;61:2505–12.
28. Aas T, Geisler S, Paulsen T, Borresen-Dale AL, Varhaug JE, Lonning PE, et al. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. *Acta Oncol* 1996;35:5–8.
29. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. *Nat Med* 1995;1:1029–34.
30. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. *Hum Pathol* 1996;27:1050–5.
31. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. *J Natl Cancer Inst* 1996;88:173–82.
32. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. *J Pathol* 1994;172:5–12.
33. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. *J Natl Cancer Inst* 1996;88:1054–9.
34. Shao ZM, Wu J, Shen ZZ, Nguyen M. p53 mutation in plasma and its prognostic value in breast cancer patients. *Clin Cancer Res* 2001;7:2222–7.
35. Gonzalez R, Silva JM, Sanchez A, Dominguez G, Garcia JM, Chen XQ, et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. *Ann Oncol* 2000;11:1097–104.
36. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt J. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. *J Clin Oncol* 1999;17:1983–7.
37. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. *J Clin Oncol* 2000;18:3651–64.
38. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987;235:177–82.
39. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. *J Clin Oncol* 1990;8:103–12.
40. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. *Int J Cancer* 1991;49:650–5.
41. Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, DiLeo A, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas: correlation with oncogene amplification in 160 cases. *Am J Clin Pathol* 2000;113:675–82.
42. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. *Stem Cells* 1998;16:413–28.
43. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. *J Clin Pathol* 2000;53:374–81.
44. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. *J Clin Oncol* 2001;19:2714–21.
45. Foy CA, Parkes HC. Emerging homogeneous DNA-based technologies in the clinical laboratory. *Clin Chem* 2001;47:990–1000.
46. Wittwer CT, Kuskawa N. Real-time PCR. In: Persing D, Tenover F, Relman D, White T, Tang Y, Versalovic J, Unger B, eds. *Diagnostic molecular microbiology: principles and applications*. Washington, DC: ASM Press, 2002;in press.
47. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. *Biotechniques* 1997;22:130–8.
48. Rasmussen RP. Quantification on the LightCycler. In: Wittwer CT, Meuer S, Nakagawara K, eds. *Rapid cycle real-time PCR: methods and applications*. Heidelberg: Springer Verlag, 2001:21–34.
49. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. *Trends Genet* 1998;14:272–6.
50. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. *Nat Genet* 1999;23:41–6.
51. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II α gene amplification and deletion in breast cancer. *Genes Chromosomes Cancer* 1999;26:142–50.
52. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase II α and other prognostic factors for epirubicin

- chemotherapy in advanced breast cancer. *Br J Cancer* 1998;77:2267–73.
53. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, et al. Amplification and deletion of topoisomerase II α associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. *Am J Pathol* 2000;156:839–47.
 54. Bernard PS, Pritham GH, Wittwer CT. Color multiplexing hybridization probes using the apolipoprotein E locus as a model system for genotyping. *Anal Biochem* 1999;273:221–8.
 55. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. *Genes Chromosomes Cancer* 1995;14:71–5.
 56. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. *Nat Med* 1996;2:811–4.
 57. Shi MM. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. *Clin Chem* 2001;47:164–72.
 58. Ferretti G, Curigliano G, Pastorino U, Cittadini A, Flamini G, Calabro MG, et al. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. *Clin Cancer Res* 2000;6:2393–400.
 59. Borreson A-L, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersoen TI, et al. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. *Proc Natl Acad Sci U S A* 1991;88:8405–9.
 60. Chen TJ, Boles RG, Wong LJ. Detection of mitochondrial DNA mutations by temporal temperature gradient gel electrophoresis. *Clin Chem* 1999;45:1162–7.
 61. Taylor GR. Enzymatic and chemical cleavage methods. *Electrophoresis* 1999;20:1125–30.
 62. Moore L, Godfrey T, Eng C, Smith A, Ho R, Waldman FM. Validation of fluorescent SSCP analysis for sensitive detection of p53 mutations. *Biotechniques* 2000;28:986–92.
 63. Marsh DJ, Theodosopoulos G, Howell V, Richardson AL, Benn DE, Proos AL, et al. Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography. *Neoplasia* 2001;3:236–44.
 64. Gundry CN, Bernard PS, Herrmann MG, Reed GH, Wittwer CT. Rapid F508del and F508C assay using fluorescent hybridization probes. *Genet Test* 1999;3:365–70.
 65. Lay MJ, Wittwer CT. Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR. *Clin Chem* 1997;43:2262–7.
 66. Nauck M, Marz W, Wieland H. Evaluation of the Roche Diagnostics LightCycler-Factor V Leiden mutation detection kit and the LightCycler-prothrombin mutation detection kit. *Clin Biochem* 2000;33:213–6.
 67. von Ahnen N, Oellerich M, Schutz E. Use of two reporter dyes without interference in a single-tube rapid-cycle PCR: α_1 -antitrypsin genotyping by multiplex real-time fluorescence PCR with the LightCycler. *Clin Chem* 2000;46:156–61.
 68. Bernard PS, Ajioka RS, Kushner JP, Wittwer CT. Homogeneous multiplex genotyping of hemochromatosis mutations with fluorescent hybridization probes. *Am J Pathol* 1998;153:1055–61.
 69. Nauck M, Hoffmann MM, Wieland H, Marz W. Evaluation of the apo E genotyping kit on the LightCycler. *Clin Chem* 2000;46:722–4.
 70. Worm J, Aggerholm A, Guldborg P. In-tube DNA methylation profiling by fluorescence melting curve analysis. *Clin Chem* 2001;47:1183–9.
 71. Crockett AO, Wittwer CT. Fluorescein-labeled oligonucleotides for real-time PCR: using the inherent quenching of deoxyguanosine nucleotides. *Anal Biochem* 2001;290:89–97.
 72. Yarbro JW, Page DL, Fielding LP, Partridge EE, Murphy GP. American Joint Committee on Cancer prognostic factors consensus conference. *Cancer* 1999;86:2436–46.
 73. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. *J Clin Oncol* 2002;20:325–34.
 74. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. *Cancer Res* 2001;61:8887–95.
 75. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. *Semin Oncol* 2002;29:37–46.
 76. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. *Semin Oncol* 2002;29:27–36.
 77. Tucker RA, Unger ER, Holloway BP, Swan DC. Real-time PCR-based fluorescent assay for quantitation of human papillomavirus types 6, 11, 16, and 18. *Mol Diagn* 2001;6:39–47.